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Preoperative Idoxuridine and Radiation For Large Soft Tissue 
Sarcomas: Clinical Results With Five-Year Follow-Up 
Vernon K. Sondak, MD, John M. Robertson, MD, Jeffrey J. Sussman, MD, Patricia A. Saran, RN, 
Alfred E. Chang, MD, and Theodore S. Lawrence, MD 
Background: Local control remains an important issue in the management of large soft tissue 
sarcomas. Radiation is the main adjuvant to surgery for local therapy of sarcomas, but it requires 
relatively high doses, hitherto considered prohibitive in areas such as the retroperitoneum. We 
developed a preoperative treatment approach to large soft tissue sarcomas that would deliver a high 
total dose of radiation administered in conjunction with the halogenated pyrimidine radiosensitizer 
idoxuridine (IdUrd). 
Methods: Thirty-seven patients with large sarcomas of the head and neck, mediastinum, retro- 
peritoneum, or extremity received three or five cycles of sequential IdUrd infusion (1000-1600 
mg/ma/d x 5 d) alternating weekly with twice daily radiation (125-150 cGy per dose) and were then 
evaluated for resection. The delivered preoperative radiation dose was up to 6250 to 7500 cGy. 
Results: Five patients (14%) had a partial response to preoperative therapy, and 28 of 37 patients 
underwent successful resection. There were no intra- or postoperative deaths. Local control was 
achieved in 19 of 28 resected patients, but in only 1 of 6 patients who remained unresectable despite 
therapy. With a median follow-up of 5.8 years, 28% of patients are alive with no evidence of disease, 
17% are alive with disease, and 53% have died of their disease. 
Conclusions: Using the dose and schedule we employed, resection of large soft tissue sarcomas 
was possible after high-dose radiation delivered in conjunction with IdUrd. Although local control 
was acceptable, the high rate of distant failure represents a limitation of any local approach to the 
treatment of large soft tissue sarcomas and suggests the need for integration of this approach with 
an effective systemic therapy. 
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Local control remains an important issue in the man- 
agement of large soft tissue sarcomas, particularly in 
sites other than the extremities. ~,2 Preoperative multimo- 
dality treatment protocols have been widely employed in 
Received May 1, 1997; accepted October 14, 1997. 
From the Departments of Surgery (VKS, JJS, PAS, AEC) and Ra- 
diation Oncology (JMR, TSL), University of Michigan Medical Center, 
Ann Arbor, Michigan. 
Dr. Robertson is now with the Department of Radiation Oncology, 
William Beaumont Hospital, Royal Oak, MI. 
Dr. Sussman is now with the Department of Surgery, University of 
Cincinnati Medical Center, Cincinnati, OH. 
Address correspondence to Vernon K. Sondak, MD, Div. of Surgical 
Oncology, University of Michigan Medical Center, 3306 Comprehen- 
sive Cancer/Geriatrics Center, Box 0932, 1500 E. Medical Center Dr., 
Ann Arbor, MI 48109-0932, USA. 
Presented at the 50th Annual Cancer Symposium of The Society of 
Sm'gical Oncology, Chicago, Illinois, March 20-23, 1997. 
the management of large, high-grade extremity sarcomas 
to avoid the need for amputation. 3'4 Preoperative treat- 
ment of nonextremity sarcomas has been more problem- 
atic. The high doses of radiation that appear to be re- 
quired to improve local control in an extremity (usually 
in excess of 6000 cGy) are above the tolerance of normal 
tissues in nonextremity sites, particularly the intestine. 
Moreover, evaluations of systemic chemotherapy in pa- 
tients with nonextremity sarcomas have been quite dis- 
appointing. 5'6 Complete surgical removal remains the 
mainstay of treatment for large soft tissue sarcomas. 
We therefore sought to develop a protocol that would 
maximize the resectability of large extremity and nonex- 
tremity soft tissue sarcomas by increasing the effective- 
ness of preoperative radiation therapy. Our approach was 
based on the use of high doses of radiation in conjunction 
with the radiation sensitizer idoxuridine (IdUrd~). IdUrd 
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is a thymidine analogue that is incorporated into the 
DNA of proliferating cells in place of thymidine, increas- 
ing the susceptibility of those cells to killing by ionizing 
radiation. 7's Sensitization by IdUrd is directly propor- 
tional to the percentage incorporated into DNA, which is, 
in turn, proportional to the total delivered dose of drug. 
The clinical application of halogenated pyrimidine radio- 
sensitizers, however, has been limited by the fact that all 
proliferating cells incorporate the agents. In large soft 
tissue sarcomas, the tumor might be adjacent to normal 
tissues (such as intestine and bone marrow) that would 
be expected to incorporate thymidine analogs efficiently. 
Indeed, a disappointingly high level of normal tissue ra- 
diosensitization was observed in patients treated with 
concurrent 5-bromo-2'-deoxyuridine (BrdUrd) and ra- 
diation. 9 Furthermore, these thymidine analogs have in- 
trinsic toxicity following long-term continuous infusion, 
which limits the total dose of sensitizer that can be de- 
livered. 10,11 
Our strategy for achieving selective radiosensitization 
of tumor versus rapidly dividing normal tissue involved 
the use of sequential, alternating administration of IdUrd 
and radiation. Cytokinetic studies have suggested that the 
intestinal mucosa and bone marrow replicate more rap- 
idly than do most human solid tumors. 12'13 Inserting a 
short treatment break between the end of sensitizer in- 
fusion and the beginning of radiation should result in a 
greater fall-off in the level of incorporation in normal 
tissue than in tumor cells. This would occur if the normal 
tissues continued to proliferate more rapidly than the 
tumor, because the fraction of thymidine replaced by 
IdUrd would be decreased by newly incorporated thymi- 
dine. The expected turnover of normal cells (e.g., migra- 
tion of mature leukocytes from the marrow or shedding 
of cells from the intestinal mucosa into the gut lumen) 
would further contribute to selective radiosensitization 
with this approach. Laboratory studies in animal models 
have confirmed that improved selectivity can be 
achieved with this sequential strategy. 14 Furthermore, it 
seemed likely that frequent short-term IdUrd infusions 
ultimately would permit the delivery of higher total 
doses with less hematologic toxicity than could be 
achieved with more prolonged exposures. This hypoth- 
esis was supported by cell culture studies, which dem- 
onstrated that, whereas radiosensitization depends solely 
on the extent  of  incorpora t ion  of  analog into 
DNA, 7"8'15A6 cytotoxicity increases with the duration of 
incorporationJ 7 Lengthening the duration of treatment 
with halogenated pyrimidines has been shown to in- 
crease systemic toxicity in animal studies as well. 13 
Based on the preclinical data cited above, we initiated 
a prospective trial in patients with locally advanced or 
unresectable (or both) soft tissue sarcomas (UMCC 
8802). Patients received up to five cycles of therapy, 
with each cycle consisting of 5 days of continuous infu- 
sion IdUrd followed 3 days later by external beam ra- 
diation. This was a phase I/II clinical trial, incorporating 
a dose escalation of the IdUrd. The initial cohort of pa- 
tients received a dose of 1000 mg/m 2 body surface area 
(BSA) per day, which was escalated in subsequent co- 
horts to 1333 mg/m2/d and then to 1600 mg/m2/d. In this 
report, we describe the mature clinical results of this 
trial, focusing on the endpoints of objective response, 




From April 1, 1989, through October 1, 1995, 38 pa- 
tients with locally advanced or unresectable soft tissue 
sarcomas were enrolled onto UMCC 8802. To be eli- 
gible, patients had to have a pathologically confirmed 
primary or recurrent soft tissue sarcoma (excluding Ew- 
ing's, osteogenic, and visceral sarcomas) in one of the 
following categories: (a) large (>5 cm), intermediate- or 
high-grade soft tissue sarcomas of the head and neck, 
trunk, or retroperitoneum; (b) large, intermediate- or 
high-grade soft tissue sarcomas arising in an extremity 
and considered unresectable without amputation; or (c) 
any soft tissue sarcoma considered to be unresectable for 
cure by standard surgical excision. Virtually all the pa- 
tients in this series were in categories b or c, as outlined 
below. Patients could not have received prior chemo- 
therapy or radiation, and had to have undergone no more 
than an incisional biopsy (i,e., measurable tumor must 
have been present). All patients were 16 years of age or 
older, and were required to have adequate organ func- 
tion, defined as follows: granulocyte count >~1500/mm 3 
and platelet count ~> 100,000/ram3; serum bilirubin ~<2.0 
mg/dL; serum creatinine ~<2.0 mg/dL; and blood urea 
nitrogen ~<40 mg/dL. 
Unresectability was determined by clinical criteria 
(physical examination and imaging studies) or by explor- 
atory operation, and was defined as the perceived inabil- 
ity to completely resect all gross tumor with a histologi- 
cally negative margin. In patients who had not undergone 
previous surgical exploration, the final determination of 
resectability was made by a multidisciplinary tumor 
board including experienced oncologic surgeons before 
protocol therapy was initiated. Although no single set of 
criteria was used, our basic prerequisites for considering 
an extremity tumor "unresectable without amputation" 
were as follows: nonmobile tumor by physical examina- 
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tion, plus tumor abutting more than 50% of the circum- 
ference of the bone or any tumor directly involving the 
joint, bones, interosseous membrane, or essential neuro- 
vascular structures. Nonextremity tumors were consid- 
ered "unresectable for cure" if they were nonmobile by 
physical examination and directly abutted bone or major 
neurovascular structures or organs that could not be re- 
sected en bloc with the tumor. It was recognized that 
some sarcomas meeting the above criteria could be re- 
sected leaving microscopic or macroscopic tumor at the 
margins. Such cases were eligible for participation in this 
trial. 
In accord with the policies of the University of Michi- 
gan and the Department of Health and Human Services, 
all patients signed an informed consent form approved 
for this purpose by the Institutional Review Board of the 
University of Michigan Hospital, which indicated that 
they were aware of the investigational nature of the treat- 
ment and the potential risks. 
IdUrd Infusion 
IdUrd (idoxnridine, 5-iodo-2'-deoxyuridine, NSC 
39661, also called IUdR) was given by continuous intra- 
venous infusion for 5 days. The dose of IdUrd adminis- 
tered was escalated during the course of the study, as 
experience at each dose level accumulated. The first 
eight patients received 1000 mg/mZ/d, the next ten re- 
ceived 1333 mg/m2/d, and subsequent patients received 
1600 mg/m2/d. In cases of severe (grade 4 hematologic 
or grade 3 or 4 nonhematologic) toxicity, the IdUrd dose 
was modified as follows: treatment was delayed until 
resolution and the dose reduced by 25% for all subse- 
quent infusions. If a second episode of the same severe 
toxicity occurred, treatment was again delayed until reso- 
lution and the IdUrd dose was reduced a further 25%. If 
a third episode occurred, the patient was taken off study 
and received no further IdUrd therapy. Toxicity was 
graded according to the NCI Common Toxicity criteria. 
Radiotherapy 
To prepare for radiotherapy, all patients were immo- 
bilized in a foam cradle and a computed tomograpbic 
(CT) scan was obtained in the treatment position. Radia- 
tion portals were individualized and designed using 
three-dimensional treatment planning. 18 The fields en- 
compassed the entire tumor plus a 3- to 6-cm margin 
during the first three cycles, whereupon the field was 
narrowed to the entire tumor plus a 1- to 1.5-cm margin 
for the remaining two cycles. The total dose to the spinal 
cord did not exceed 3900 cGy. If more than one half of 
the kidney parenchyma on one side was treated, the other 
kidney was excluded from the radiation field. Patients 
with extremity, mediastinal, or head and neck tumors 
(i.e., those with no bowel in the radiation field) received 
external beam radiation as twice daily 150-cGy fractions 
at least 4 hours apart (cumulative radiation dose for pa- 
tients completing the entire protocol: 7500 cGy). Patients 
with retroperitoneal tumors received radiation as twice 
daily 125-cGy fractions at least 4 hours apart (cumula- 
tive radiation dose for patients completing entire proto- 
col: 6250 cGy). Treatments were delivered using 6- to 
15-MV photons, 9- to 20-MeV electrons, or both. In 
cases of toxicity, the radiation dose was not modified, 
and every effort was made to avoid delays between the 
end of the IdUrd infusion and the beginning of radiation 
treatment (i.e., within one cycle). Rather, necessary dose 
delays were between cycles. 
Treatment Scheme 
Three cycles of radiosensitizer and radiation (6 weeks 
of therapy) were administered initially, whereupon all 
patients were assessed for resectability. Insofar as pos- 
sible, patients were to undergo tumor resection at that 
point and receive two additional cycles postoperatively. 
For some patients, resection still was deemed not feasible 
after three treatment cycles had been completed. These 
patients received all five cycles of therapy before resec- 
tion was attempted. In either event, tumor resection was 
performed approximately 4 weeks after the last radiation 
treatment. Once the surgical wound had healed satisfac- 
torily, patients who had received three preoperative 
cycles of therapy were treated with two additional cycles. 
Patients who had received five cycles of therapy before 
undergoing surgery did not receive any additional post- 
operative therapy. Because of the lack of demonstrated 
survival benefit in randomized studies at the time this 
study was conducted, 19 patients did not receive adjuvant 
chemotherapy. 
Assessment of Response 
Standard criteria for the assessment of response to 
therapy were employed. Clinical complete response was 
defined as the complete disappearance of all known dis- 
ease for at least 4 weeks with no evidence of new dis- 
ease. Partial response was defined as a decrease in the 
cross-product of the perpendicular diameters of the tu- 
mor by at least 50%, lasting at least 4 weeks and with no 
evidence of new disease. Progressive disease was de- 
fined as an increase in the cross-product of the perpen- 
dicular diameters of the tumor by at least 25%, or the 
development of new disease. 
Statistical Analysis 
Comparisons of outcomes between groups were done 
using X 2 analysis. A two-sided P value of <.05 was con- 
sidered significant. 
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RESULTS 
Patient Demographics and Tumor Characteristics 
Thirty-eight patients were enrolled onto this phase H I  
clinical trial. One patient was deemed ineligible when 
review of an outside incisional biopsy failed to confirm 
the diagnosis of malignancy. All other patients were fully 
eligible and evaluable for toxicity, response, and resect- 
ability. One patient was lost to follow-up postoperatively 
and is censored from analyses of disease-free and overall 
survival. The median age of eligible patients on this trial 
was 49 years (mean 46 years, range 17 to 73 years). 
There were 16 females and 21 males. All patients had 
measurable tumor, and none had received previous ra- 
diation or chemotherapy. Two patients had locally recur- 
rent tumors after prior surgical therapy; one patient pre- 
sented with potentially resectable lung metastases con- 
currently with a retroperitoneal primary tumor. The 
distribution of tumors by site, grade, and histology is 
given in Table 1. All tumors were larger than 5 cm in 
maximal diameter; 32 of 37 tumors were over 10 cm. 
Toxicity and Response to Preoperative Treatment 
All 37 eligible patients were evaluable for toxicity and 
response to preoperative treatment. The dose-limiting 
toxicity was significant stomatitis encountered at the 
1600 mg/mZ/d dose level but not at lower doses. This 
was particularly severe in the two patients with head and 
neck sarcomas, both of whom required enteral feedings 
via percutaneous, endoscopically placed gastrostomy 
tubes. Nausea, vomiting, and diarrhea often were dose- 
limiting in patients with retroperitoneal tumors. Three 
patients failed to complete preoperative therapy because 
of toxicity. One patient was taken off study because of 
prolonged grade III neutropenia and successfully com- 
pleted preoperative therapy with radiation alone without 
further IdUrd. She underwent complete resection of her 
tumor but was lost to postoperative follow-up. One pa- 
tient with a pelvic retroperitoneal sarcoma developed a 
TABLE 1. Tumor characteristics 
Tumor site Tumor grade Histologic subtypes 
Extremity 13 Grade I 
Retroperitoneum 20 Grade II 
Head and neck 2 Grade III 
Mediastinum 2 
6 MFH 12 
7 Neurofibrosarcoma 9* 




Synovial sarcoma 1 
Other 2** 
* Seven in patients with neurofibromatosis type 1. 
** One case each of extraosseous chondrosarcoma and adenosarco- 
ma. 
grade IV bilirubin increase, and one patient with a very 
large retroperitoneal sarcoma developed a grade IV bil- 
irubin increase as well as grade IV neutropenia and di- 
arrhea. Both patients completed preoperative therapy 
with radiation alone; only the latter patient was able to 
undergo resection. All three patients were considered 
nonresponders to treatment. 
During the 6- to 10-week preoperative treatment pe- 
riod, four patients developed or had progression of 
known distant metastases (lung metastases in 3 patients, 
liver metastases in 1 patient). No patient had progression 
(>25% increase) in the size of the primary tumor during 
treatment. There were no clinical complete responses, 
but five patients had partial responses, for a 14% overall 
objective response rate. Responses were seen in three of 
13 patients with extremity tumors, one of 20 patients 
with retroperitoneal tumors, and one of four patients with 
nonextremity, nonretroperitoneal tumors. Most respond- 
ers (four of five) had grade III tumors, and none had 
grade I tumors. Although relatively few patients had re- 
gression sufficient to qualify as a partial response, most 
patients had sufficient shrinkage of tumors to permit ul- 
timate resection, as discussed later. Histologic evidence 
of significant treatment effect, with posttreatment necro- 
sis in 20% to 100% of tumor cells, was seen in most 
patients. Complete tumor necrosis was found in one case, 
and extensive (>98%) necrosis was found in another 
when the tumors demonstrating a partial response were 
resected. The remaining objective responders had lesser 
degrees of posttreatment necrosis. 
Resectability After Preoperative Treatment 
Only one of four patients who developed distant me- 
tastases underwent resection of the treated primary tumor 
for local control. Of the remaining 33 patients, 27 un- 
derwent resection, for a total of 28 of 37 (76%) of all 
eligible patients. Histologically negative margins were 
achieved in 13 of the 28 resections (46%), and gross 
residual disease was left in only two patients (one of 
whom had 100% tumor necrosis and remains alive and 
continuously disease-free almost 8 years postopera- 
tively), strongly suggesting that in at least some cases 
preoperative treatment allowed curative resections that 
would not have been possible otherwise. Six patients 
remained unresectable despite preoperative treatment, 
and all but one ultimately progressed in the treated field. 
Among the 13 patients with extremity sarcomas consid- 
ered to require amputation in the absence of preoperative 
treatment, 10 patients underwent successful resection 
(seven with histologically negative margins), two pa- 
tients developed distant metastases and never had surgi- 
cal treatment of their primary tumors, and one patient 
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failed to respond sufficiently to permit resection with 
limb preservation. This patient refused amputation and 
was treated with further radiation and IdUrd alone; he 
subsequently died of distant disease with control of his 
primary tumor. 
In no case did the preoperative treatment preclude or 
significantly hamper the definitive resection. There were 
no intraoperative or postoperative deaths. 
Late Toxicity 
Thirty-six patients were evaluable for late toxicity. 
One patient with a low-grade retrohepatic sarcoma de- 
veloped acute cholangitis 18 months after completion of 
therapy and died with no evidence of residual tumor at 
necropsy. This was felt to be a late death from toxicity, 
as the bile duct was within the treated field. Adhesive 
bowel obstructions necessitating reoperation were seen 
in two patients, one at 2 months and the other at 3 years 
after resection of large retroperitoneal sarcomas. No 
cases of radiation enteritis have been encountered, with a 
maximum follow-up of 7.5 years from the completion of 
therapy for the longest surviving patient. In addition to 
the two reoperations for bowel obstruction, four other 
patients had late toxicity requiring surgery: one patient's 
extremity wound dehisced, requiring myocutaneous flap 
coverage; one patient with a paraspinous sarcoma devel- 
oped a cerebrospinal fluid leak requiring omental flap 
closure; one patient with a pelvic sarcoma developed a 
persistent ureteral stricture, ultimately requiring nephrec- 
tomy; and one patient with a groin sarcoma developed a 
pathologic fracture of the proximal femur requiring open 
fixation. 
Outcome 
With a median follow-up of 5.8 years, and a minimum 
follow-up of 2.5 years for surviving patients, there have 
been nine local recurrences among 36 evaluable patients 
(25%). Four of these recurrences developed simulta- 
neous with or subsequent to distant metastasis. Local 
recurrence was somewhat more common in nonextrem- 
ity sites, with two local recurrence among 10 resected 
extremity tumors as opposed to five of 14 resected ret- 
roperitoneal tumors and two of three resected head and 
neck or mediastinal sarcomas. Fourteen of 36 patients are 
alive (39%), but only ten (28%) are alive and flee of 
disease. This includes one patient who developed a soli- 
tary lung metastasis, which was successfully resected, 
who remains disease-flee 3 years postthoracotomy. Dis- 
tant metastases developed in 50% of patients, distributed 
equally among the different primary sites. Of note, dis- 
tant disease developed in two of the five patients with 
large, low-grade sarcomas (all retroperitoneal). Although 
the total number of patients is too small to adequately 
assess the influence of histologic subtype on outcome, 
there was no obvious trend for a better or worse outcome 
for patients by histologic subtype. For example, two of 
nine patients with neurofibrosarcomas (both of which 
arose in conjunction with neurofibromatosis type 1) are 
alive and continuously disease-free more than 5 years 
after completion of therapy; this percentage does not 
differ significantly from the group as a whole (22% ver- 
sus 28%). 
Among the five patients who achieved a partial re- 
sponse, all are alive and four have no evidence of dis- 
ease, compared to nine alive among the remaining 31 
evaluable patients. This difference in overall survival be- 
tween responders and nonresponders is statistically sig- 
nificant (P2 < .02, X 2 test). Hence, there appears to be a 
correlation between response to preoperative treatment 
and outcome. 
DISCUSSION 
Our main goal in conducting this protocol was to in- 
tensify local therapy for patients with large soft tissue 
sarcomas, with the hope that this would improve resect- 
ability and local control and perhaps translate into long- 
term disease-free survival. We were able to successfully 
resect large extremity and nonextremity sarcomas after 
significant doses of externally delivered radiation with- 
out excessive morbidity or mortality. Ten of 13 extremity 
sarcoma patients underwent radical resections after 4500 
cGy of radiation, delivered in conjunction with the ra- 
diosensitizer idoxuridine, with two major local compli- 
cations and no amputations or deaths. Fourteen of 20 
patients with retroperitoneal sarcomas underwent resec- 
tions after either 3750 or 6250 cGy of radiation plus 
sensitizer, again with acceptable morbidity and no mor- 
tality. One patient with a mediastinal tumor underwent 
uneventful resection of tumor adjacent to the aorta and 
esophagus after 7500 cGy of radiation plus sensitizer. 
Although the scheduling of the radiation (every-other- 
week treatment with twice-daily fractions) probably 
helped to minimize the toxicity of treatment, the admin- 
istration of a sensitizer and the high cumulative dose of 
radiation delivered meant that tumors and adjacent nor- 
mal tissues received very close to maximal amounts of 
local therapy. Significantly, histologically negative mar- 
gins were achieved in 46% of the patients undergoing 
resection (70% of the patients with extremity tumors), 
despite the fact that virtually all patients were felt to have 
been unresectable to negative margins prior to radiation 
as a condition of entry onto the study. 
This study was not randomized, and was not intended 
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to answer questions such as the relative value of pre- 
versus postoperative radiation or the benefit of delivering 
a radiation sensitizer. Idoxuridine recently has been re- 
ported to improve survival when used as a radiosensitizer 
for the treatment of anaplastic astrocytomas. 2° One large 
trial of idoxuridine given by continuous infusion concur- 
rently with radiation in patients with unresectable sarco- 
mas has been performed, and revealed local control rates 
that the authors suggested represented a potential im- 
provement over radiation alone, l° There are few, if any, 
series in the literature evaluating sarcoma patients with 
characteristics similar to the patients in our study, limit- 
ing our ability to compare our results to those of others 
using different treatment protocols. Nonetheless, a sur- 
vey of the available literature suggests that our local 
control and resectability rates are at least comparable to 
those reported from other centers. For example, Eilber et 
al. 2a recently reported on 99 selected patients with high- 
grade extremity sarcomas treated with preoperative che- 
motherapy and radiation followed by surgery. They re- 
ported a limb-sparing resection rate of 95%, a local re- 
currence rate of 20%, and a 5-year disease-free survival 
of 70%, after a median follow-up of 6 years. The average 
size of the tumors in their series was smaller than that in 
our study, so our results seem to compare favorably. 
Casper et al.22 reported on 23 patients with high-grade 
extremity sarcomas treated with preoperative chemo- 
therapy and postoperative radiation with no objective 
responses seen, a limb-sparing resection rate of 96%, an 
isolated local recurrence rate of 9%, and a disease-free 
survival of 41% after a median follow-up of 39 months. 
In contrast to extremity sarcomas, where preoperative, 
multimodality therapy is widely used, no consensus ex- 
ists as to whether and how to treat nonextremity sarco- 
mas preoperatively. Most published series have em- 
ployed resection followed by radiation, chemotherapy, or 
both, with varying results. Among the best results with 
such an approach are those reported by Karakousis et 
a l .Y with a resectability rate of 95%, a local recurrence 
rate of 31%, and a 5-year survival of 63% in 87 consec- 
utively treated patients. Results of other series have not 
been quite as favorable. Sindelar et al., 24 in a series of 
resectable retroperitoneal sarcoma patients, conducted a 
prospective randomized trial of intraoperative plus post- 
operative external beam radiation versus postoperative 
radiation alone. Sixty percent of patients developed local 
recurrences, with no overall benefit seen for intraopera- 
tive radiotherapy and a high incidence of complications 
of intraoperative treatment. Interestingly, in this series 
34% of patients developed "disabling" radiation enteri- 
tis, a complication we did not observe even though we 
administered a higher total dose of external beam radia- 
tion. 
Since our protocol was completed, a meta-analysis of 
the effect of adjuvant chemotherapy on outcome in pa- 
tients with soft tissue sarcomas has been conductedY 
This analysis suggested a small benefit for adjuvant che- 
motherapy in decreasing local recurrence and improving 
disease-free and, possibly, overall survival. It remains 
unclear if the benefits of adjuvant chemotherapy are seen 
equally in sarcomas arising in all areas, or whether a 
disproportionate benefit accrues to patients with extrem- 
ity tumors. Nonetheless, the results of this meta- 
analysis--particularly when combined with the high rate 
of distant failure encountered on our protocol--make the 
incorporation of systemic chemotherapy into multimo- 
dality treatment protocols for nonextremity sarcomas an 
attractive prospect. Since completing our protocol, we 
have treated a small number of patients with large ret- 
roperitoneal sarcomas with preoperative chemotherapy 
without radiation. With relatively short follow-up, the 
local recurrence rate appears to be higher than what we 
saw with our preoperative radiation and radiosensitizer 
protocol. Consequently, we believe that the integration 
of both chemotherapy and high-dose radiation will be 
required in the next generation of multimodality therapy 
protocols for nonextremity sarcoma patients. It is par- 
ticularly interesting in this regard to note that IdUrd has 
been reported to be a potent chemosensitizer in vitro as 
well as a radiosensitizer, 26'27 and phase I clinical trials of 
IdUrd plus chemotherapy already have been con- 
ducted. 28 
One additional caveat regarding preoperative chemo- 
therapy must be mentioned. It has been reported that 
patients who have a good response to preoperative che- 
motherapy fare better than patients who do not, implying 
an effect of the chemotherapy on microscopic distant 
disease. 29 The treatment regimen we tested in our pro- 
tocol did not involve systemic antitumor chemotherapy, 
and the systemic use of a halogenated pyrimidine radio- 
sensitizer would not be expected to provide any direct 
cytotoxic effects on sarcoma cells. Nonetheless, we saw 
a statistically significant trend for patients whose tumors 
responded to therapy to have improved disease-free and 
overall survival compared to nonresponders. This raises 
the possibility that responding tumors may be an inher- 
ently more favorable group, regardless of the treatment 
to which they are responding, and calls into question the 
validity of analysis of responders versus nonresponders 
as a means for assessing overall efficacy of a given treat- 
ment. 
In conclusion, we found that a short-term continuous 
infusion of IUdR and high-dose radiation is tolerable, 
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and that this therapy can lead to sufficient regression of 
locally advanced and even unresectable sarcomas to per- 
mit successful resection with acceptable local control 
rates. The high incidence of distant failure represents a 
major limitation of this or any local regional approach to 
very large sarcomas. Nonetheless, we believe our results 
warrant consideration for the integration of high-dose 
radiation and radiation sensitizers into modern multimo- 
dality therapy as the next logical step. The apparent cor- 
relation of response and outcome suggests that caution 
should be used in concluding there is a systemic effect of 
any preoperative therapy; we believe that there was none 
in our trial. Finally, although randomized trials ulti- 
mately will be required to determine if radiosensitizers 
have any role in the treatment of locally advanced sar- 
comas, we believe the next generation of clinical trials 
should focus on the integration of these aggressive local 
approaches with modem systemic treatment. 
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